These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37837424)

  • 41. Identifying Isoononin and Candidissiol as Rho-associated protein kinase 1 (ROCK1) inhibitors: a combined virtual screening and MD simulation approach.
    Alotaibi BS; Joshi J; Hasan MR; Khan MS; Alharethi SH; Mohammad T; Alhumaydhi FA; Elasbali AM; Hassan MI
    J Biomol Struct Dyn; 2023; 41(14):6749-6758. PubMed ID: 35965440
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Gutkin E; Gusev F; Gentile F; Ban F; Koby SB; Narangoda C; Isayev O; Cherkasov A; Kurnikova MG
    Chem Sci; 2024 Jun; 15(23):8800-8812. PubMed ID: 38873063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives.
    Atashrazm F; Dzamko N
    Clin Pharmacol; 2016; 8():177-189. PubMed ID: 27799832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
    Greshock TJ; Sanders JM; Drolet RE; Rajapakse HA; Chang RK; Kim B; Rada VL; Tiscia HE; Su H; Lai MT; Sur SM; Sanchez RI; Bilodeau MT; Renger JJ; Kern JT; McCauley JA
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2631-5. PubMed ID: 27106707
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ganoderic Acid A targeting
    Ahmad F
    Aging Med (Milton); 2023 Sep; 6(3):272-280. PubMed ID: 37711263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Network metrics, structural dynamics and density functional theory calculations identified a novel Ursodeoxycholic Acid derivative against therapeutic target Parkin for Parkinson's disease.
    Naha A; Banerjee S; Debroy R; Basu S; Ashok G; Priyamvada P; Kumar H; Preethi AR; Singh H; Anbarasu A; Ramaiah S
    Comput Struct Biotechnol J; 2022; 20():4271-4287. PubMed ID: 36051887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-α-synuclein is normalized by LRRK2 modulation.
    Andersen MA; Christensen KV; Badolo L; Smith GP; Jeggo R; Jensen PH; Andersen KJ; Sotty F
    Neurobiol Dis; 2018 Aug; 116():13-27. PubMed ID: 29680709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods.
    Gancia E; De Groot M; Burton B; Clark DE
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2520-2527. PubMed ID: 28408230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural binding site comparisons reveal Crizotinib as a novel LRRK2 inhibitor.
    Bolz SN; Salentin S; Jennings G; Haupt VJ; Sterneckert J; Schroeder M
    Comput Struct Biotechnol J; 2021; 19():3674-3681. PubMed ID: 34285770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models.
    Li T; He X; Thomas JM; Yang D; Zhong S; Xue F; Smith WW
    PLoS One; 2015; 10(3):e0122461. PubMed ID: 25816252
    [TBL] [Abstract][Full Text] [Related]  

  • 51. From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2.
    Mancini A; Mazzocchetti P; Sciaccaluga M; Megaro A; Bellingacci L; Beccano-Kelly DA; Di Filippo M; Tozzi A; Calabresi P
    Front Cell Neurosci; 2020; 14():158. PubMed ID: 32848606
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach.
    Agrahari AK; Doss GPC; Siva R; Magesh R; Zayed H
    J Theor Biol; 2019 May; 469():163-171. PubMed ID: 30844370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
    Göring S; Taymans JM; Baekelandt V; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Searching for Novel Anaplastic Lymphoma Kinase Inhibitors: Structure-Guided Screening of Natural Compounds for a Tyrosine Kinase Therapeutic Target in Cancers.
    Adnan M; Koli S; Mohammad T; Siddiqui AJ; Patel M; Alshammari N; Bardakci F; Elasbali AM; Hassan MI
    OMICS; 2022 Aug; 26(8):461-470. PubMed ID: 35925819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
    Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
    PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
    Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
    J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein.
    Brzozowski CF; Hijaz BA; Singh V; Gcwensa NZ; Kelly K; Boyden ES; West AB; Sarkar D; Volpicelli-Daley LA
    Acta Neuropathol Commun; 2021 Nov; 9(1):180. PubMed ID: 34749824
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.
    Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.